Following our general assembly held in June, Biotechnet is pleased to announce the appointment of four new advisors to its advisory board.
Composed of experienced professionals representing industry, applied research, and innovation policy, the advisory board provides strategic insights and supports us as we continue to expand our network and impact.
We wish the new advisors a warm welcome and look forward to working together!
Prof. Dr. Dominic Hoepfner, Novartis
Dominic earned his Ph.D. from the University of Basel in cellular dynamics, followed by a postdoc in the Netherlands focused on peroxisome biogenesis. He joined Novartis Biomedical Research in 2005 and has worked on target identification through high-throughput genetics. He currently leads the functional genomics platform in Discovery Sciences Basel and serves as co-chair of the external innovation committee. He also teaches genetics and drug discovery at the University of Basel and the biotech school in Strasbourg.
Prof. Dr. Valérie Barbié, Swiss Institute of Bioinformatics
Valérie Barbié trained as a computer sciences engineer in France and the USA. After working at the CNRS, she joined the pharma industry and specialized in biomarkers analysis and personalized medicine. She now leads the Clinical Bioinformatics group at the Swiss Institute of Bioinformatics, which provides expertise and support to hospitals and industry for the organization, analysis and interpretation of patient-related data.
Mr. Andreas Meier, Member of the National Council (Mitte)
Andreas Meier is a Member of the Swiss National Council for the Centre Party (Die Mitte). He serves on the Committees for Science, Education and Culture (WBK) and for Oversight (GPK). He is President of CarnaLibertas and ProWiBa, a board member of SFATA, a trustee of Gen Suisse, and member of the Board of Directors of the Hightech Center Aargau.
Dr. Massimo Nobile, Swiss Biotech Center
Massimo Nobile obtained his PhD in biology from the University of Lausanne. He joined CimArk in 2010, where he manages Life Sciences initiatives and provides support to innovative companies developing biopharmaceuticals and in vitro diagnostics. Dr. Nobile has been managing the Swiss Biotech Center since its creation in 2016 and has extensive expertise on turning biomedical research into products for the European market.
